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Abstract  
Background: Rapid spread of the SARS-CoV-2 virus and concern for viral transmission by ambulatory 
patients with minimal to no symptoms underline the importance of identifying early or subclinical 
symptoms of Covid-19 infection. Two such candidate symptoms include anecdotally reported loss of 
smell and taste. Understanding the timing and association of smell/taste loss in Covid-19 may help 
facilitate screening and early isolation of cases. 
 
Methods: A single-institution, cross-sectional study evaluating patient-reported symptoms with a 
focus on smell and taste was conducted using an internet-based platform on adult subjects who 
underwent testing for Covid-19. Logistic regression was employed to identify symptoms associated 
with Covid-19 positivity. 
 
Results: A total of 1480 patients with influenza-like symptoms underwent Covid-19 testing between 
March 3 through 29, 2020. Our study captured 59 of 102 (58%) Covid-19-positive patients and 203 of 
1378 (15%) Covid-19-negative patients. Smell and taste loss were reported in 68% (40/59) and 71% 
(42/59) of Covid-19-positive subjects, respectively, compared to 16% (33/203) and 17% (35/203) of 
Covid-19-negative patients (p<0.001). Smell and taste impairment were independently and strongly 
associated with Covid-19-positivity (anosmia: adjusted odds ratio [aOR] 10.9, 95%CI:5.08-23.5; 
ageusia: aOR 10.2 95%CI:4.74-22.1); whereas, sore throat was associated with Covid-19-negativity 
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(aOR 0.23, 95%CI:0.11-0.50). Of patients who reported Covid-19-associated loss of smell, 74% 
(28/38) reported resolution of anosmia with clinical resolution of illness. 
 
Conclusions: In ambulatory individuals with influenza-like symptoms, chemosensory dysfunction was 
strongly associated with Covid-19 infection and should be considered when screening symptoms. 
Most will recover chemosensory function within weeks paralleling resolution of other disease-
related symptoms. <PE-FRONTEND> 
 
Introduction: 
The Covid-19 pandemic caused by the SARS-CoV-2 virus continues to spread at an exponential rate 
with recent concerns of significant viral transmission through asymptomatic or mildly symptomatic 
patients.1 Anecdotal reports suggest smell and taste loss are potential early symptom or subclinical 
markers of Covid-19 infection. A preliminary study from Iran showed a significant increase in new-
onset anosmia since the Covid-19 outbreak.2 An Italian report of 59 hospitalized Covid-19 patients 
found that 33% reported a chemosensory disorder.3 However, it remains unclear if these findings are 
unique to Covid-19 infections requiring hospitalization, causally related to Covid-19 infection, or 
simply due to more widespread recognition of post-viral anosmia. Insight into the timing and 
association of smell/taste loss and Covid-19 is critical as patients with acute anosmia may be 
otherwise asymptomatic carriers of infection who may unwittingly facilitate the spread of disease. 
 
Methods:  
Study Design and Population 
A single institution, cross-sectional study evaluating patient-reported symptoms with a focus on 
smell and taste was conducted using an internet-based platform (Qualtrics) on adult subjects who 
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underwent polymerase chain reaction (PCR)-confirmed testing for Covid-19 between March 3, 2020 
and March 29, 2020. An initial email invitation to a 27-question survey was sent to 102 subjects who 
tested Covid-19-positive and 1378 subjects who tested Covid-19-negative with a follow-up phone 
call. Sense of smell at baseline, at the time of Covid-19 testing, and at the time of survey were 
assessed using a subjective olfaction score. Questions were based off a continuous 10-point slide bar 
such as 0: no sense of smell, 10: normal sense of smell, with scores from 1 to 9 indicating 
progressively increasing severity of hyposmia. This study was approved by the Institutional Review 
Board of University of California San Diego (IRB# 200485). 
 
Statistical Analysis 
Categorical variables were evaluated by chi-squared (χ2) test. Unadjusted odds ratios (OR) with 95% 
confidence intervals (CI) were calculated by univariable logistic regression, with Covid-19 test result 
considered as the independent variable. Adjusted OR were calculated using multivariable logistic 
regression analysis, a priori criteria for variable inclusion in the multivariable model included: [1] 
maximum of 6 variables to minimize potential model overfitting, [2] magnitude of association with 
Covid-19 positivity of at least 2-fold (i.e. OR >2.0 or OR < 0.5), [3] statistically significant associations 
(p<0.05), *4+ we prioritized “any symptoms” (eg. any symptoms reported during the entire disease 
period) over “presenting symptoms” (eg. initial symptoms of presentation) because we had no a 
priori hypothesis for the natural history of anosmia and thus believed that inputting “any symptoms” 
for our multivariate correlation analyses would be more sensitivity for establishing associations 
between anosmia/ageusia and Covid-19-status. Given the known colinear relationship between 
anosmia and ageusia, each variable was adjusted separately as a dependent variable. Goodness-of-
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fit was performed for both final multivariable models (anosmia and ageusia). All permutations of 
models tested showed  p-values > 0.05, demonstrating that goodness-of-fit of both final models as 
evaluated by both Pearson’s method (anosmia p=0.64, ageusia p=0.44), as well as Hosmel-
Lemeshow’s method (anosmia p=0.36, ageusia p=0.11), demonstrated that our models fit the data 
well. Analysis was performed using Stata 15.1 software (StataCorp, College Station, Texas). 
 
Results: 
A total of 59 Covid-19-positive (58% response rate) and 203 Covid-19-negative subjects completed 
the survey (15% response rate) between March 31 and April 3, 2020. Demographics and clinical 
characteristics of the two cohorts are summarized in Table 1. There were no differences in regard to 
age (grouped by decade) or rate of illness improvement between the two groups. Hospital 
admissions rates were low and comparable in both groups (4/58 [7%] of Covid-19-positive patients 
and 14/200 [7%] Covid-19-negative patients, χ2 test p=0.98), with predominantly ambulatory cases 
responding to the survey. The patients who were later found to be Covid-19-negative were admitted 
for evaluation of fever and/or dyspnea. Sex distribution in Covid-19-positive patients was balanced 
but skewed toward females (65%) in Covid-19-negative patients. 
 
Olfactory and gustatory impairment was reported in (40/59) 68% and (42/59) 71% of Covid-19-
positive patients, respectively, compared to 16% and 17% of Covid-19-negative patients (χ2 test 
p<0.001). Two patients reported acute ageusia without acute anosmia due to a pre-existing history 
of baseline chronic rhinosinusitis-associated anosmia. Self-reported symptoms associated with 
Covid-19-positivity in order of descending frequency included fatigue (81%), ageusia (71%), fever 
  
 
 
This article is protected by copyright. All rights reserved. 
 
6 
(70%), anosmia (68%), myalgia or arthralgia (63%), diarrhea (48%), and nausea (27%). Sore throat 
was associated with Covid-19-negativity (60% versus 32% in Covid-19-positive patients). Fever was 
the most common presenting symptom (54%), while 22% reported anosmia at initial presentation of 
Covid-19-positive illness. 
 
Compared to other symptoms of Covid-19 infection, loss of smell and taste showed the largest 
magnitudes of association with Covid-19 positivity (anosmia: OR 10.9, 95% CI: 5.6-21.0; ageusia: OR 
11.9 95% CI 6.1-23.2, Table 2, left column). Multivariable logistic regression adjusting for 
myalgia/arthralgia, fatigue, fever, nausea, and sore throat demonstrated that both smell and taste 
impairment independently associated with Covid-19-positivity (anosmia: aOR 10.9, 95% CI: 5.08-
23.5; taste: aOR 10.2 95% CI 4.74-22.1, Table 2, middle and right columns). Conversely, sore throat 
was independently associated with Covid-19 negativity, with Covid-19-negative patients being 4- to 
5-fold more likely to report sore throat as a symptom (aOR 0.23, 95% CI 0.11-0.50). Beyond smell 
loss, taste loss, and sore throat, only nausea was found to be consistently and independently 
associated with Covid-19 positivity. None of the evaluated comorbidities listed in Table 1 associated 
with Covid-19-status.  
  
Patterns of Covid-19-related olfactory/gustatory impairment demonstrate a profound to complete 
anosmia/ageusia, with a significant majority achieving spontaneous improvement (Figure 1 & Figure 
2). Notably, the degree of Covid-19-related anosmia and ageusia correlate closely in affected 
individuals. No patients in this study received treatment for olfactory or gustatory loss.  Among 
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Covid-19-positive subjects who experienced smell loss, 29/40 (72.5%) reported improvement at time 
of survey (18% by <1 week, 37.5% by 1-2 weeks, 18% by 2-4 weeks). 
 
The majority of Covid-19-positive patients had improvement of olfaction and taste that temporally 
correlated with clinical resolution of illness (Figure 3 A). Seventy-four percent (28/38, 2 failed to 
respond) of affected patients reported both improvement of olfactory dysfunction and overall illness 
symptoms. Those who did not experience improvement in smell also had not felt improvement in 
other clinical symptoms. Four patients reported clinical improvement without olfactory 
improvement; however, these patients were less than 2 weeks from onset of symptoms. Similarly, of 
those who reported no improvement of smell loss, 82% were diagnosed <2 weeks prior (Figure 3 B). 
 
Discussion 
This study demonstrates the prevalence and unique presentation of chemosensory impairment in 
Covid-19-positive compared to Covid-19-negative individuals, both presenting with similar influenza-
like symptoms. We found a significant association between smell/ taste loss and Covid-19 infection 
as these chemosensory impairments were at least 10-fold more common in Covid-19-positive cases. 
Of those who reported olfactory dysfunction, the loss was typically profound rather than mild. 
Despite the slightly higher reported incidence of ageusia compared to anosmia, we know that loss of 
taste is linked with one’s loss of smell and the differences in reporting can be attributed to the few 
patients with baseline rhinosinusitis-induced anosmia.  
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We have also demonstrated that most patients reported improvement of smell and taste at the time 
of the survey, typically less than two weeks post-diagnosis. Similarly, the overall symptoms of 
disease improved or resolved during that time frame. In select cases (10%), patients reported early 
resolution of clinical symptoms without return of olfaction. It is possible that some of these 
individuals may regain sense of smell with more time as 82% of them were tested for Covid-19 less 
than 2 weeks ago. Overall, these findings may offer reassurance that patients with ambulatory 
Covid-19 infection and associated anosmia/hyposmia may recover olfactory function within weeks 
paralleling resolution of other disease-related symptoms.  
 
Of the Covid-19-positive respondents in this study, most did not require hospitalization, and none 
required intubation, suggesting that a relatively mild subset of Covid-19 infection was captured. This 
is in contrast to the hospital-based survey of Covid-19 infections by Giacomelli et al3 which reported 
rates of chemosensory loss at half the level of our subjects. This suggests that ambulatory and 
inpatient Covid-19 cases may follow fundamentally different  clinical courses. We hypothesize that 
perhaps ambulatory cases are in part the result of nasal-centric viral spread, whereas patients 
requiring hospitalization may be experiencing a more pulmonary-centric viral infection leading to 
increased rate of respiratory failure and need for hospitalization. Future studies are warranted to 
investigate this hypothesis because, if found to be true, beyond potential screening markers for 
Covid-19 infection positivity, anosmia/ageusia may carry some prognostic potential on severity of 
disease. 
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Post-viral anosmia is a common cause of smell loss in adults and is known to be associated with 
many human viral strains, including other coronaviruses.4 Early studies evaluating mechanisms of 
SARS-CoV2-mediated olfactory loss have suggested neurotrophic targeting of olfactory neurons 
versus infection of non-neural olfactory epithelial cells.5,6 The short-lived Covid-19-related olfactory 
loss found in our study favors a model in which SARS-CoV2 targets the olfactory epithelium, which 
can rapidly regenerate and repair after viral clearance.   
 
Larger scale studies on epidemiologically balanced datasets are warranted to accurately determine 
the overall incidence and prevalence of Covid-19-related anosmia/hyposmia, and to determine its 
predictive value for Covid-19 infection. This study is limited by a short sampling period at a single 
institution, as well as the subjective assessment used to determine smell/taste impairment. 
Furthermore, by surveying respondents after Covid-19-testing, we risk post-hoc interpretations of 
smell and taste loss through their knowledge of their diagnosis, a potential recall bias especially in 
the context of pervasive anecdotal reports of Covid-19-related anosmia. Specifically, it remains 
possible that patients with smell loss in the Covid-19-positive group were more likely to respond 
based on media reporting of smell loss and/or desire to share their experience, as compared to the 
Covid-19-negative group. However, the comparison of clinical characteristics and outcomes between 
the Covid-19-positive and negative cohorts was valuable in determining true associations as all 
individuals were deemed persons under investigation (PUI) prior to study enrollment and 
demonstrated minor differences in baseline characteristics beyond Covid19-status. One must also 
consider the sensitivity and potential false-negativity of the PCR-based Covid-19 assays. Two of our 
subjects had previously tested negative for Covid-19 infection and subsequent testing resulted in a 
positive test.  
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In this study, olfaction was evaluated using a subjective olfaction score of 1-10 as a true visual analog 
scale (VAS) was unable to be performed through the online survey platform. It has been previously 
shown that compared to more objective batteries of olfactory testing, subjective reporting of sense 
of smell is specific but not sensitive.7 Typically, people do not recognize their loss of smell and thus 
tend to under-report smell loss. However, we must weigh this possibility against the potential 
information bias of Covid-19 test positivity. Future studies using well-validated instruments of 
olfaction, will be important to corroborate these patient-reported subjective assessments of 
olfactory loss. 
  
Conclusion:  
There is a strong association of olfactory and gustatory impairment with Covid-19 infection and a 
temporal relationship of improvement of these symptoms with resolution of overall clinical illness in 
this predominantly ambulatory population. This study offers support for using smell/taste loss as a 
symptom for heightened screening of Covid-19 infections in an effort to decrease the risk of disease 
transmission from mildly symptomatic cases. 
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Table 1: Baseline characteristics. 
Differences in self-reported clinical feature distributions across Covid-19-positive and Covid-19-
negative patients were evaluated by chi-squared test with p-values reported in the right column. 
Annotations: *1 patient did not answer question on age group,  **2 patients did not answer 
question on gender, ***4 patients did not answer question on improvement of illness, ****4 
patients did not answer question on hospital admission. All other reported results based on 100% 
response rates.  
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Table 1: Baseline characteristics 
  
Covid-19-positive 
n=59 
n (%) 
Covid-19-negative 
n=203 
n (%) p-value 
Age group (years)* 18-29 10 (17.0) 26 (12.9) 0.19 
  30-39 11 (18.6) 67 (33.2)   
  40-49 17 (28.8) 39 (19.3)   
  50-59 9 (15.3) 36 (17.8)   
  60-69 7 (11.9) 19 (9.4)   
  70-79 5 (8.5) 10 (5.0)   
  > 80 0 5 (2.5)   
Gender** Male 29 (49.2) 69 (34.0) 0.033 
  Female 29 (49.2) 132 (65.0)   
  Gender Diverse 1 (1.7) 0   
Improvement of illness*** No 8 (13.6) 38 (18.7) 0.66 
  Yes 50 (84.8) 162 (79.8)   
Hospital admission**** No 54 (93.1) 186 (93.0) 0.98 
  Yes 4 (6.9) 14 (7.0)   
Any symptoms Fatigue 48 (81.4) 116 (57.1) 0.001 
  Ageusia 42 (71.2) 35 (17.2) <0.001 
  Fever 41 (69.5) 87 (42.9) <0.001 
  Anosmia 40 (67.8) 33 (16.3) <0.001 
  Cough 39 (66.1) 156 (76.9) 0.096 
  Headache 39 (66.1) 99 (48.8) 0.019 
  Myalgia/Arthralgia 37 (62.7) 65 (32.0) <0.001 
  Dyspnea 32 (54.2) 88 (43.4) 0.14 
  Diarrhea 28 (47.5) 50 (24.6) 0.001 
  Nasal obstruction 28 (47.5) 91 (44.8) 0.72 
  Sore throat 19 (32.2) 122 (60.1) <0.001 
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  Rhinorrhea 18 (30.5) 83 (40.9) 0.15 
  Nausea 16 (27.1) 23 (11.3) 0.004 
Presenting symptoms Fatigue 25 (42.4) 62 (30.5) 0.089 
  Ageusia 12 (20.3) 10 (4.9) <0.001 
  Fever 32 (54.2) 53 (26.1) <0.001 
  Anosmia 13 (22.0) 9 (4.4) <0.001 
  Cough 21 (35.6) 104 (51.2) 0.034 
  Headache 25 (42.4) 40 (19.7) <0.001 
  Myalgia/Arthralgia 20 (33.9) 39 (19.2) 0.017 
  Dyspnea 7 (11.9) 47 (23.2) 0.059 
  Diarrhea 5 (8.5) 16 (7.9) 0.88 
  Nasal obstruction 11 (18.6) 43 (21.2) 0.67 
  Sore throat 10 (17.0) 92 (45.3) <0.001 
  Rhinorrhea 6 (10.2) 40 (19.7) 0.09 
  Nausea 3 (5.1) 8 (3.9) 0.7 
Comorbidities Allergic rhinitis 20 (33.9) 77 (37.9) 0.57 
  Other immunosuppressed state 9 (15.3) 32 (15.8) 0.92 
  Hypertension 8 (13.6) 30 (14.8) 0.82 
  Diabetes 5 (8.5) 15 (7.4) 0.78 
  Cardiac disease 3 (5.1) 13 (6.4) 0.71 
  Chronic lung disease 3 (5.1) 31 (15.3) 0.04 
  Cancer 2 (3.4) 10 (4.9) 0.62 
  Sinus disease 2 (3.4) 20 (9.9) 0.12 
  History of head trauma 1 (1.7) 13 (6.4) 0.16 
  Neurologic disease 0 6 (3.0) 0.18 
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Table 2: Self-reported clinical feature associations with Covid-19-positivity. 
Associations of self-reported clinical feature associations to Covid-19-status were tested using 
univariable (left column, reporting unadjusted odds ratios) and multivariable (middle and right 
columns, reporting adjusted odds ratios) logistic regression models. Separate multivariable 
regression models were conducted for anosmia (middle column) and ageusia (right column), given 
the observed collinearity of these variables.  Annotations: +variables included in the multivariable 
regression analysis *multivariable regression including anosmia, **multivariable regression including 
ageusia, 95% CI: 95% confidence interval. Abbreviations: OR, odds ratio; aOR, adjusted odds ratio.   
 
Table 2: Self-reported clinical feature associations with Covid-19-positivity. 
  
Univariable 
Regression 
Odds Ratio 
OR (95% CI) 
 
p-value 
Multivariable 
Regression* 
Adjusted Odds Ratio  
aOR (95% CI) 
 
p-value 
Multivariable 
Regression** 
Adjusted Odds Ratio  
aOR (95% CI) 
 
p-value 
Age group (years) 0.72 (0.33 - 1.60) 0.43         
Gender 0.53 (0.30 - 0.96) 0.036         
Improvement of illness 1.47 (0.64 - 3.35) 0.36         
Hospital admission 0.98 (0.31 - 3.11) 0.98     
 
  
Any symptoms             
    Ageusia+ 11.86 (6.06 - 23.19) <0.001 -- -- 10.23 (4.74 - 22.09) <0.001 
    Anosmia+ 10.85 (5.60 - 21.01) <0.001 10.92 (5.08 - 23.53) <0.001 -- -- 
    Myalgia/Arthralgia+ 3.57 (1.95 - 6.54) <0.001 1.74 (0.79 - 3.84) 0.17 1.53 (0.71 - 3.33) 0.28 
    Fatigue+ 3.27 (1.61 - 6.67) 0.001 1.53 (0.61 - 3.84) 0.37 1.23 (0.50 - 3.04) 0.66 
    Fever+ 3.03 (1.63 - 5.65) <0.001 1.55 (0.71 - 3.40) 0.27 1.67 (0.77 - 3.60) 0.19 
    Nausea+ 2.91 (1.42 - 5.98) 0.004 2.86 (1.16 - 7.01) <0.001 2.71 (1.07 - 6.83) 0.035 
    Diarrhea 2.76 (1.51 - 5.05) 0.001  --  -- --  --  
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    Headache 2.05 (1.12 - 3.75) 0.02 -- -- -- -- 
    Dyspnea 1.55 (0.86 - 2.77) 0.064 -- -- -- -- 
    Nasal obstruction 1.11 (0.62 - 1.99) 0.72 -- -- -- -- 
    Rhinorrhea 0.63 (0.34 - 1.18) 0.096 -- -- -- -- 
    Cough 0.59 (0.31 - 1.10) 0.098 -- -- -- -- 
    Sore throat+ 0.32 (0.17 - 0.58) <0.001 0.20 (0.09 - 0.44) <0.001 0.23 (0.11 - 0.50) <0.001 
Presenting symptoms         
 
  
    Fatigue 1.67 (0.92 - 3.04) 0.091     
 
  
    Ageusia 4.93 (2.01 - 12.10) <0.001     
 
  
    Fever 3.35 (1.84 - 6.11) <0.001     
 
  
    Anosmia 6.09 (2.46 - 15.11) <0.001     
 
  
    Cough 0.53 (0.29 - 0.96) 0.036     
 
  
    Headache 3.00 (1.61 - 5.58) 0.001     
 
  
    Myalgia/Arthralgia 2.16 (1.13 - 4.10) 0.019     
 
  
    Dyspnea 0.45 (0.19 - 1.05) 0.064     
 
  
    Diarrhea 1.08 (0.38 - 3.09) 0.88     
 
  
    Nasal obstruction 0.85 (0.41 - 1.78) 0.67     
 
  
    Sore throat 0.25 (0.12 - 0.51) <0.001     
 
  
    Rhinorrhea 0.46 (0.19 - 1.15) 0.096     
 
  
    Nausea 1.31 (0.34 - 5.09) 0.70     
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Figure 1: Temporal association of olfactory score and Covid-19-testing. 
Spaghetti plot of all Covid-19-positive individuals (n=59) reporting olfactory scores (0: no sense of 
smell, 10: normal sense of smell) at baseline, at time of Covid-19 diagnosis, and at time of survey 
completion (post-Covid-19 diagnosis either <1 week, 1-2 weeks, or 2-4 weeks). Rows represent time 
elapsed between testing positive for Covid-19 and completion of survey. The left and middle 
columns reflect patient stratification into groups who failed to improve (red lines, left column) and 
those who achieved improvement/resolution of clinical symptoms (blue lines, middle column) at the 
time of survey completion. The right column displays aggregated results (mean, SEM) stratified by 
clinical improvement.  
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Figure 2: Temporal association of taste score and Covid-19-testing. 
Spaghetti plot of all Covid-19-positive individuals (n=59) reporting taste scores (0: no sense of taste, 
10: normal sense of taste) at baseline, at time of Covid-19 diagnosis, and at time of survey 
completion (post-Covid-19 diagnosis either <1 week, 1-2 weeks, or 2-4 weeks). Rows represent time 
elapsed between testing positive for Covid-19 and completion of survey. The left and middle 
columns reflect patient stratification into groups who failed to improve (red lines, left column) and 
those who achieved improvement/resolution of clinical symptoms (blue lines, middle column) at the 
time of survey completion.  The right column displays aggregated results (mean, SEM) stratified by 
clinical improvement.  
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Figure 3: Temporal relationship between olfactory improvement and clinical improvement 
following Covid-19 infection. 
A. Histogram demonstrating the reported time to improvement in Covid-19-positive subjects with 
olfactory loss and its relationship to patient-reported time to overall clinical improvement (n=38, 2 
subjects did not answer time to clinical improvement). 
B. Histogram demonstrating the time post-Covid-19 diagnosis (approximate time elapsed since 
testing positive) in subjects who reported no improvement of smell loss (n=11); 81.8% were 
diagnosed <2 weeks prior. 
 
 
 
 
 
